Amidst ESA Upheaval, FDA Used Mircera Review To Outline Trial “Wish List”
Executive Summary
FDA's review of Roche's Mircera BLA became a forum for the agency to set forth a "wish list" for future development of erythropoietin stimulating agents that reflected the seismic upheavals in the conventional understanding of the safety of erythropoietin products